Abstract: The application describes a T-cell expressing a chimeric antigen receptor (‘CAR T-cell’) containing superparamagnetic iron-based particles (‘loaded CAR T-cell’) for use in treating a tumor. Said loaded CAR T-cell exhibits a reduced cytokine release upon binding to a cell of the tumor expressing an antigen being recognized by the CAR of the CAR T-cell, compared to a CAR T-cell not containing superparamagnetic iron-based particles (‘unloaded CAR T-cell’) under the same conditions. Furthermore, an in vitro method of generating a CAR T-cell containing superparamagnetic iron-based particles is described, whereby such loaded CAR T-cells are generated.

Abstract: The invention relates to dendritic cells, the NF?B signaling pathway of which has been manipulated by RNA transfection, to the manufacture Thereof and to use thereof.

Abstract: The invention relates to dendritic cells, the NF?B signaling pathway of which has been manipulated by RNA transfection, to the manufacture thereof and to use thereof.

Abstract: The invention relates to dendritic cells, the NF?B signaling pathway of which has been manipulated by RNA transfection, to the manufacture thereof and to use thereof.

Abstract: The invention relates to dendritic cells, the NF?B signaling pathway of which has been manipulated by RNA transfection, to the manufacture thereof and to use thereof.

Abstract: The invention relates to dendritic cells, the NF?B signaling pathway of which has been manipulated by RNA transfection, to the manufacture thereof and to use thereof.

Abstract: The invention provides improved methods of producing dendritic cells (“DCs”) that transiently express a membrane homing peptide and optionally at least one additional antigen. These DCs have the ability to home to lymph nodes in vivo. In some embodiments, these DCs can be administered to a patient intravenously and can subsequently home to lymph nodes and stimulate an immune response. The methods and DCs of the invention are useful for the treatment of various diseases and disorders.

Abstract: The invention relates to T cells transiently transfected with RNA, especially RNA encoding a T cell receptor and/or FoxP3, and to methods of transfecting T cells with RNA by electroporation. Compositions of the invention include an effector T cell transiently transfected with RNA encoding a T cell receptor (TCR) specific for an antigen, wherein the T cell demonstrates effector function specific for cells presenting the antigen in complex with an MHC molecule. Treg cells comprising an exogenous RNA encoding FoxP3 are also provided. The transfected T cells are useful for immunotherapy, particularly in the treatment of tumors, pathogen infection, autoimmune disease, transplant rejection and graft versus host disease.